Revenue (¥ bn, bars) · net margin (%, line)
Source: securities reports
FY2010 · consolidated
Revenue$13.8B
Net income-$319M
Net margin-2.3%
→
FY2026 · consolidated
Revenue$10.6B
Net income$218M
Net margin2.1%
After the financial crisis the old problem returned in a new form. Mitsui posted net losses for three consecutive years — ¥1.0 billion in the year to March 2012, ¥8.1 billion in 2013 and $237.2M (¥25bn) in 2014 — as Chinese capacity additions and structurally low cracker utilization pushed commodity earnings down. It was, in outline, the 1980s over again: the petrochemical business begun with pooled Mitsui capital in 1955 was still, half a century on, the main source of earnings volatility. Tanaka Toshikazu, president from June 2009, began the response by running the Chiba crackers jointly with Idemitsu Kosan and by consolidating the non-petrochemical businesses into Mitsui Chemicals Agro and Mitsui Chemicals Tohcello.
Tannowa Tsutomu, president from June 2014, made the shift explicit: keep rationalizing commodity petrochemicals, and concentrate capital on three growth domains — life and healthcare, mobility, ICT. Photochromic lens materials were bought from Corning in 2014 and the Kulzer dental materials business from Heraeus in January 2018, giving the company an oral-care pillar of global scale. Operating profit rose from $396.8M (¥42bn) in the year to March 2014 to $910.3M (¥102bn) in 2017 and ¥103.4 billion in 2018. Thirty years after the “Beyond Petrochemicals” slogan, the escape from commodity dependence had finally become a matter of capital allocation rather than rhetoric.
Hashimoto Osamu, president from June 2019, extended it into an explicitly two-axis company, running petrochemicals and the growth domains on different logics: ARRK and Honshu Chemical brought in during 2021, a polyurethane venture stake taken from SKC, agrochemicals bought from Meiji Holdings in January 2022. In 2025, with Ichimura Satoshi as president and Yoshida Osamu as chief financial officer, the emphasis moved again — from adding acquisitions to disciplining the capital already deployed. ROE and ROIC were put first, a planned dividend increase was converted into a share buyback, policy shareholdings held in the retirement benefit trust were sold, and the company committed to returning some $1.0B (¥150bn) to shareholders over four years. The joint cracker consolidation with Idemitsu, meanwhile, is set for fiscal 2027.